Partner with us icon Partner with Us
Corporate Actions
Marksans Pharma soars after Q4 PAT jumps 64% YoY

26-May-26   13:56 Hrs IST
On a consolidated basis, the company reported a net profit of Rs 148.12 crore in Q4 FY26, up 63.60% YoY and 30.85% QoQ.

Revenue from operations rose 20.84% YoY to Rs 856.11 crore in Q4 FY26, while increasing 13.48% QoQ.

Gross profit stood at Rs 465.5 crore in Q4 FY26, up 21.5% YoY and 6.2% QoQ. Gross margin improved to 54.4% from 54.1% in Q4 FY25, supported by favourable product mix, softening raw material prices and forex tailwinds.

Profit before tax stood at Rs 199.99 crore in Q4 FY26, up 72.27% YoY and 32.78% QoQ.

EBITDA stood at Rs 195.4 crore in Q4 FY26, up 54% YoY and 21.6% QoQ. EBITDA margin expanded sharply to 22.8% from 17.9% in the year-ago period and 21.3% in Q3 FY26, aided by operating leverage and tight cost controls.

On the cost front, raw material costs increased 40.89% YoY to Rs 264.97 crore, while employee expenses rose 9.81% YoY to Rs 106.75 crore. Interest costs climbed 83.97% YoY to Rs 6.31 crore, while depreciation expenses increased 6.77% YoY to Rs 24.28 crore.

The company said quarterly growth was driven by new launches in Australia and the UK, while price erosion in the UK market stabilized during the quarter. Marksans Pharma also launched its first Rx branded products in Australia during Q4 FY26.

Management added that Australia and New Zealand revenues grew 61% YoY, while the US and North America business increased 24% YoY, supported by traction from new product launches and expansion across OTC store brands.

The company noted that gross margin expansion was supported by softening raw material prices, favourable product mix and forex gains. However, sequential gross margin moderated due to rising input costs linked to ongoing geopolitical tensions.

For the full year FY26, net profit rose 9.81% YoY to Rs 417.9 crore, while revenue increased 12.51% YoY to Rs 2,950.93 crore. PBT for FY26 rose 11.23% YoY to Rs 560.55 crore.

EBITDA for FY26 stood at Rs 600.8 crore, up 12.8% YoY, while EBITDA margin improved marginally to 20.4% from 20.3% in FY25.

Net cash flow from operating activities improved sharply to Rs 458.12 crore in FY26 from Rs 206.66 crore in FY25.

The company reported a cash balance of Rs 990 crore as of 31 March 2026.

The board recommended a final dividend of Rs 0.90 per equity share of face value Re 1 each for FY26.

Marksans Pharma is engaged in the research, manufacturing and marketing of pharmaceutical formulations across regulated and emerging markets, with a strong presence in OTC and prescription products.

Powered by Capital Market - Live News

Attention Investors:
Stock Brokers can accept securities as margin from clients only by way of pledge in the depository system w.e.f. September 1, 2020. || Update your mobile number & email Id with your stock broker/depository participant and receive OTP directly from depository on your email id and/or mobile number to create pledge. || Pay 20% upfront margin of the transaction value to trade in cash market segment. || Investors may please refer to the Exchange's Frequently Asked Questions (FAQs) issued vide circular reference NSE/INSP/45191 dated July 31, 2020 and NSE/INSP/45534 dated August 31, 2020 and other guidelines issued from time to time in this regard. || Check your Securities /MF/ Bonds in the consolidated account statement issued by NSDL/CDSL every month. || KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary. || No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account.